Home › Trials › NCT06820463

Evaluating a new treatment for metastatic colorectal cancer

A Phase 2, Open-Label, Randomized, Master Protocol Study to Evaluate Safety and Efficacy of Multiple Treatment Combinations With Telisotuzumab Adizutecan in Subjects With Metastatic Colorectal Cancer

PHASE2 · AbbVie · NCT06820463

This study is testing a new drug combined with standard chemotherapy to see if it helps adults with metastatic colorectal cancer feel better and improve their condition.

Quick facts

PhasePHASE2
Study typeInterventional
Enrollment390 (estimated)
Ages18 Years and up
SexAll
SponsorAbbVie (industry)
Drugs / interventionstelisotuzumab, bevacizumab, panitumumab, pantitumumab
Locations44 sites (Duarte, California and 43 other locations)
Trial IDNCT06820463 on ClinicalTrials.gov

What this trial studies

This study assesses the safety and efficacy of telisotuzumab adizutecan when combined with standard chemotherapy agents like oxaliplatin, fluorouracil, leucovorin, and targeted therapies such as bevacizumab or panitumumab in adults with metastatic colorectal cancer. The trial is structured in two stages, starting with dose escalation to determine the maximum tolerable dose before randomizing participants into treatment arms. The goal is to evaluate adverse events and changes in disease activity associated with this investigational drug.

Who should consider this trial

Good fit: Ideal candidates include adults with metastatic colorectal cancer who have an ECOG performance status of 0 or 1 and measurable disease.

Not a fit: Patients who have previously received systemic treatments targeting c-Met or topoisomerase inhibitors may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could provide a new effective option for patients with metastatic colorectal cancer.

How similar studies have performed: Other studies have shown promise with similar combinations of chemotherapy and targeted therapies, but this specific approach with telisotuzumab adizutecan is novel.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
* Laboratory values meeting the criteria within the protocol.
* Has measurable disease per response evaluation criteria in solid tumors (RECIST) v1.1.

Exclusion Criteria:

* Prior systemic regimen containing c-Met targeting agent(s) (e.g., antibody, antibody drug conjugate, bispecific) and/or any topoisomerase inhibitor(s) (e.g., irinotecan).
* History of other malignancies within 5 years prior to screening, except for malignancies with a negligible risk of metastasis or death.

Where this trial is running

Duarte, California and 43 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.

View on ClinicalTrials.gov →

Conditions: Metastatic Colorectal Cancer, AndroMETa-CRC-533, Telisotuzumab Adizutecan

Last reviewed 2026-05-15 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.